Condition
Malignant Tumor of Breast
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 10 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
10 shownTart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced NeuropathyNCT06268665 · 2024-08-15
RECRUITINGA Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerNCT06471673 · 2024-05-29
UNKNOWNStudy of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCNCT05191004 · 2022-09-01
WITHDRAWNImplantation of CEST and CESL MRI Methods for Detection of Breast TumorsNCT05305937 · 2022-05-01
UNKNOWNFacilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer SurvivorsNCT05364450 · 2021-08-17
COMPLETEDStudy of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsNCT04541225 · 2020-12-08
TERMINATEDLifestyles and Breast CancerNCT04174391 · 2020-05-29
ACTIVE_NOT_RECRUITINGAlternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast CancerNCT03007979 · 2017-06-15
COMPLETEDInvestigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer SurvivorsNCT02611544 · 2015-12-01
COMPLETEDMiracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by EverolimusNCT02229136 · 2014-09-04
COMPLETEDCommon interventions
Enhanced Usual CareBEHAVIORAL2FulvestrantDRUG2NUV-422DRUG2Acceptance and Commitment TherapyBEHAVIORAL1Acceptance Commitment TherapyBEHAVIORAL1BC1 cell lineBIOLOGICAL1Bria-OTS regimen and CPI (tislelizumab)BIOLOGICAL1Bria-OTS regimen and CPI (tislelizumab) expansion cohortBIOLOGICAL1Circulating tumor cell blood drawPROCEDURE1Cognitive Behavioral TherapyBEHAVIORAL1GoserelinDRUG1LetrozoleDRUG1Low-fat dietBEHAVIORAL1Mediterranean diet supplemented with extra-virgin olive oilBEHAVIORAL1Miracle Mouthwash Plus HydrocortisoneDRUG1MRI scanDEVICE1Optional research biopsyPROCEDURE1PalbociclibDRUG1PrednisoloneDRUG1Research blood drawPROCEDURE1Survivorship EducationBEHAVIORAL1Tart Cherry JuiceDRUG1Tumor biopsy (optional)PROCEDURE1
Leading sponsors
Trial status mix
COMPLETED4
UNKNOWN2
ACTIVE_NOT_RECRUITING1
RECRUITING1
TERMINATED1
WITHDRAWN1
Phase mix
PHASE25
NA4
PHASE13
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.